Yahoo
NYSEArca - Delayed Quote USD

Capital Group Core Equity ETF (CGUS)

45.17 -0.04 (-0.09%)
At close: September 4 at 4:00:00 PM EDT
45.23 +0.06 (+0.13%)
After hours: September 4 at 7:59:54 PM EDT
Trade CGUS on Coinbase
Chart Range Bar
Loading chart for CGUS
  • Previous Close 45.21
  • Open 45.24
  • Bid 45.17 x 290000
  • Ask 45.22 x 720000
  • Day's Range 45.09 - 45.32
  • 52 Week Range 37.19 - 46.80
  • Volume 1,166,637
  • Avg. Volume 1,129,709
  • Net Assets 11.81B
  • NAV 44.88
  • PE Ratio (TTM) 27.12
  • Yield 0.82%
  • YTD Daily Total Return 12.10%
  • Beta (5Y Monthly) 0.94
  • Expense Ratio (net) 0.33%

The fund invests primarily in common stocks of companies that the investment adviser believes demonstrate the potential for appreciation and/or dividends. The fund normally invests at least 80% of its assets in equity securities. It may invest up to 15% of its assets, at the time of purchase, in securities of issuers domiciled outside the United States. The fund is designed for investors seeking both capital appreciation and income. It is non-diversified.

Capital Group

Fund Family

Large Blend

Fund Category

11.81B

Net Assets

2022-02-22

Inception Date

Performance Overview

View More

Trailing returns as of 9/2/2026. Category is Large Blend.

YTD Return

CGUS
12.10%
Category
5.14%

1-Year Return

CGUS
18.18%
Category
27.72%

3-Year Return

CGUS
20.87%
Category
19.34%

People Also Watch

Holdings

View More

Top 10 Holdings (42.23% of Total Assets)

Symbol Company % Assets
NVDA 7.28%
MSFT 7.09%
AVGO 5.41%
AMZN 4.98%
LLY 3.75%
META 3.55%
GOOGL 3.14%
TSM 2.48%
AAPL 2.40%
AMAT 2.15%

Sector Weightings

Research Reports

View More
  • Daily – Vickers Top Insider Picks for 09/03/2026

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

  • Boston Scientific Earnings: Competitive Pressure Closing in on Key Growth Areas

    Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.

    Rating
    Price Target
  • Raising target price and EPS estimates on outlook

    Johnson & Johnson is a diversified global healthcare company that develops, manufactures, and markets products in two business segments: Innovative Medicine (formerly Pharmaceuticals) and MedTech.

    Rating
    Price Target
  • Johnson & Johnson Earnings: Steady Growth and Good Near-Term Visibility; Maintaining Our FVE

    Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of the total revenue is generated in the United States.

    Rating
    Price Target

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: